The intestinal mucosa harbors trillions of commensal bacteria that provide the host with nutrients and contribute to resistance to infections but, in certain instances, also potentiate the generation of proinflammatory cells. Recent studies unveil how this delicate balance is achieved and how it can be manipulated for therapeutic purposes.
Planning a Selective Attack
Discriminating between invasive dangerous microbes and mutualistic commensal bacteria at the mucosal barriers is a challenging task. Lora Hooper and colleagues (Mukherjee et al., 2013) show that C-type lectins of the RegIII family are well suited for this complex task. They report that RegIIIa mediates bacterial killing by binding to phospholipids in the bacterial membrane, forming a hexameric oligomeric pore that renders the membrane permeable. Importantly, lipopolysaccharide, a component of the outer layer of the Gram-negative bacterial cell wall, inhibits the activity of RegIIIa, thus explaining how RegIIIa specifically kills Gram-positive bacteria. This mechanism may allow efficient protection of the intestinal barrier against invasive bacteria while simultaneously tolerating the existence of abundant commensal Gram-negative species. Mukherjee, S., et al. (2014) . Nature 505, [103] [104] [105] [106] [107] 
Microbiota against the Cancer
Beyond their local effect in the mucosa, intestinal commensal microbes can affect inflammation and immunity systemically. Trinchieri, Goldszmid, and colleagues (Iida et al., 2013) report that disruption of the microbiota by antibiotic treatment impairs tumor response to immunotherapy and platinum chemotherapy in a mouse model of subcutaneous tumor. In the absence of an intact microbiota, myeloid cells infiltrating the tumor microenvironment, which are important mediators of the effects of immunotherapy and contribute to the cytotoxic effect of anticancer drugs, produce less inflammatory cytokines and are deficient in the production of reactive species of oxygen. These results highlight the importance of the microbiota in determining the outcome of the response to cancer therapy. Indeed, in a related report, Zitvogel and colleagues (Viaud et al., 2013) observe that cyclophosphamide, an important drug for cancer treatment, alters the composition of the intestinal microbiota and promotes translocation of selected Grampositive bacteria species to the secondary lymphoid organs. In that location, these bacteria stimulate the differentiation of effector Th17 cells that, in turn, are required to mediate the cytotoxic antitumor effect of the drug. The molecular mechanism behind the induction of Th17 cells by these members of the microbiota is still unclear. Therefore, these two studies show that manipulation of the intestinal microbiota may potentially be useful to boost chemotherapy and immunotherapy for cancer in humans. Iida, N., et al. (2013) . Science 342, 967-970. Viaud, S., et al. (2013) . Science 342, [971] [972] [973] [974] [975] [976] .
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